United States Financial Markets News
Sign up for free!
Get instant access to all of our market news and analysis with our free REST API.
Oops... There was a problem with your request.
- Country "dk" not found.
Search entities
Discover all 32,649 supported financial entities for United States financial markets here.
Latest news
Live response for past 24 hours
{
"meta": {
"found": 277,
"returned": 10,
"limit": 10,
"page": 1
},
"data": [
{
"uuid": "1bbe7aa3-1bb4-4e76-9eeb-84d2a81e8fbc",
"title": "BeOne Medicines (ONC) Reveals Promising SEQUOIA Trial Results | ONC Stock News",
"description": "BeOne Medicines (ONC) is set to unveil promising findings from its pivotal global Phase 3 SEQUOIA trial, focusing on BRUKINSA, during two rapid oral presentatio",
"keywords": "GuruFocus, Article, News, GuruFocus News, ONC",
"snippet": "BeOne Medicines (ONC, Financial) is set to unveil promising findings from its pivotal global Phase 3 SEQUOIA trial, focusing on BRUKINSA, during two rapid oral ...",
"url": "https://www.gurufocus.com/news/2900238/beone-medicines-onc-reveals-promising-sequoia-trial-results-onc-stock-news",
"image_url": "https://static.gurufocus.com/logos/0C0000B0F6.png?20",
"language": "en",
"published_at": "2025-06-01T21:15:32.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "BGNE",
"name": "BeiGene, Ltd.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 39.831963,
"sentiment_score": 0.1128,
"highlights": [
{
"highlight": "Positive Points\n\n<em>BeiGene</em> <em>Lt[+223 characters]",
"sentiment": 0.8625,
"highlighted_in": "main_text"
},
{
"highlight": "<em>BeiGene</em> <em>Ltd</em> (ONC) has [+292 characters]",
"sentiment": -0.6369,
"highlighted_in": "main_text"
}
]
}
],
"similar": [
{
"uuid": "9f01ec79-e7e1-4567-b21a-df84f9d1312e",
"title": "AstraZeneca (AZN): ENHERTU Demonstrates Significant Survival Boost in Gastric Cancer Trial | AZN Stock News",
"description": "The DESTINY-Gastric04 phase 3 study has yielded promising results for ENHERTU, an innovative HER2-targeting DXd antibody-drug conjugate crafted by Daiichi Sanky",
"keywords": "GuruFocus, Article, News, GuruFocus News, AZN",
"snippet": "The DESTINY-Gastric04 phase 3 study has yielded promising results for ENHERTU, an innovative HER2-targeting DXd antibody-drug conjugate crafted by Daiichi Sanky...",
"url": "https://www.gurufocus.com/news/2900231/astrazeneca-azn-enhertu-demonstrates-significant-survival-boost-in-gastric-cancer-trial-azn-stock-news",
"image_url": "https://static.gurufocus.com/logos/0C00000AGP.png?20",
"language": "en",
"published_at": "2025-06-01T21:00:28.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "AZN",
"name": "AstraZeneca PLC",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 49.821407,
"sentiment_score": 0.457025,
"highlights": [
{
"highlight": "The DESTINY-Gastric04 phase 3 study has [+182 characters]",
"sentiment": 0.6808,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts Forecast\n\nBased on [+283 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed estimate data can be found[+253 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Based on GuruFocus estimates, the estima[+239 characters]",
"sentiment": 0.8176,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed data can be found on the <[+228 characters]",
"sentiment": 0.8934,
"highlighted_in": "main_text"
},
{
"highlight": "Positive Points\n\n<em>AstraZeneca</em> <e[+267 characters]",
"sentiment": 0.9565,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> <em>PLC</em> (AZN) [+222 characters]",
"sentiment": 0.8074,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> (AZN): ENHERTU Demonstrates Significant Survival Boost in Gastric Cancer Trial | AZN Stock News",
"sentiment": -0.2263,
"highlighted_in": "title"
}
]
},
{
"symbol": "ZEG.DE",
"name": "AstraZeneca PLC",
"exchange": null,
"exchange_long": null,
"country": "de",
"type": "equity",
"industry": "Healthcare",
"match_score": 49.814663,
"sentiment_score": 0.457025,
"highlights": [
{
"highlight": "The DESTINY-Gastric04 phase 3 study has [+182 characters]",
"sentiment": 0.6808,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts Forecast\n\nBased on [+283 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed estimate data can be found[+253 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Based on GuruFocus estimates, the estima[+239 characters]",
"sentiment": 0.8176,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed data can be found on the <[+228 characters]",
"sentiment": 0.8934,
"highlighted_in": "main_text"
},
{
"highlight": "Positive Points\n\n<em>AstraZeneca</em> <e[+267 characters]",
"sentiment": 0.9565,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> <em>PLC</em> (AZN) [+222 characters]",
"sentiment": 0.8074,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> (AZN): ENHERTU Demonstrates Significant Survival Boost in Gastric Cancer Trial | AZN Stock News",
"sentiment": -0.2263,
"highlighted_in": "title"
}
]
},
{
"symbol": "AZNCF",
"name": "AstraZeneca PLC",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 49.814663,
"sentiment_score": 0.457025,
"highlights": [
{
"highlight": "The DESTINY-Gastric04 phase 3 study has [+182 characters]",
"sentiment": 0.6808,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts Forecast\n\nBased on [+283 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed estimate data can be found[+253 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Based on GuruFocus estimates, the estima[+239 characters]",
"sentiment": 0.8176,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed data can be found on the <[+228 characters]",
"sentiment": 0.8934,
"highlighted_in": "main_text"
},
{
"highlight": "Positive Points\n\n<em>AstraZeneca</em> <e[+267 characters]",
"sentiment": 0.9565,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> <em>PLC</em> (AZN) [+222 characters]",
"sentiment": 0.8074,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> (AZN): ENHERTU Demonstrates Significant Survival Boost in Gastric Cancer Trial | AZN Stock News",
"sentiment": -0.2263,
"highlighted_in": "title"
}
]
}
]
},
{
"uuid": "1acc11e5-1a8a-403a-ae6d-a3df1cc4a828",
"title": "Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO | ALLO Stock News",
"description": "Allogene Therapeutics' (ALLO) ALLO-316 shows a 31% response rate in advanced renal cell carcinoma with high CD70 expression. Four out of five patients m",
"keywords": "GuruFocus, Article, News, GuruFocus News, ALLO",
"snippet": "Allogene Therapeutics' (ALLO, Financial) ALLO-316 shows a 31% response rate in advanced renal cell carcinoma with high CD70 expression.\n\nFour out of five patien...",
"url": "https://www.gurufocus.com/news/2900184/allogene-therapeutics-provides-updated-phase-1-data-highlighting-durable-responses-with-allo316-in-heavily-pretreated-advanced-renal-cell-carcinoma-at-asco-allo-stock-news",
"image_url": "https://static.gurufocus.com/logos/0C0000BIIE.png?20",
"language": "en",
"published_at": "2025-06-01T16:00:23.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "ALLO",
"name": "Allogene Therapeutics, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 66.951675,
"sentiment_score": 0.376667,
"highlights": [
{
"highlight": "<em>Allogene</em> <em>Therapeutics</em>'[+323 characters]",
"sentiment": 0.2551,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Allogene</em> <em>Therapeutics</em>,[+164 characters]",
"sentiment": 0.6249,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Allogene</em> <em>Therapeutics</em> Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO | ALLO Stock News",
"sentiment": 0.25,
"highlighted_in": "title"
}
]
}
]
}
]
},
{
"uuid": "ca6df2c2-a4bb-4d5c-bdcf-3c7edc860497",
"title": "TempusAI (TEM) Unveils Fuses Program to Enhance Precision Medicine | TEM Stock News",
"description": "TempusAI (TEM) has introduced its new Fuses program, aiming to utilize its unique dataset to provide critical insights into patient care and medical research. B",
"keywords": "GuruFocus, Article, News, GuruFocus News, TEM",
"snippet": "TempusAI (TEM, Financial) has introduced its new Fuses program, aiming to utilize its unique dataset to provide critical insights into patient care and medical ...",
"url": "https://www.gurufocus.com/news/2900237/tempusai-tem-unveils-fuses-program-to-enhance-precision-medicine-tem-stock-news",
"image_url": "https://static.gurufocus.com/images/global_logo_twitter_card.png",
"language": "en",
"published_at": "2025-06-01T21:15:24.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "TEM",
"name": "Tempus AI Inc",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Technology",
"match_score": 32.599243,
"sentiment_score": 0.296,
"highlights": [
{
"highlight": "<em>Tempus</em> <em>AI</em> <em>Inc</em>[+138 characters]",
"sentiment": 0.296,
"highlighted_in": "main_text"
}
]
}
],
"similar": [
{
"uuid": "3c32ccbb-50e8-414d-a546-0f91f65ab9e7",
"title": "UiPath (PATH) Sees Price Target Increase Amid Execution Stability | PATH Stock News",
"description": "Bank of America has adjusted its price target for UiPath (PATH), raising it from $10 to $12 while maintaining an Underperform rating on the stock. The upgrade f",
"keywords": "GuruFocus, Article, News, GuruFocus News, PATH",
"snippet": "Bank of America has adjusted its price target for UiPath (PATH, Financial), raising it from $10 to $12 while maintaining an Underperform rating on the stock. Th...",
"url": "https://www.gurufocus.com/news/2900190/uipath-path-sees-price-target-increase-amid-execution-stability-path-stock-news",
"image_url": "https://static.gurufocus.com/images/global_logo_twitter_card.png",
"language": "en",
"published_at": "2025-06-01T16:45:11.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "PATH",
"name": "UiPath Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Technology",
"match_score": 88.8833,
"sentiment_score": 0.419711,
"highlights": [
{
"highlight": "Bank of America has adjusted its price t[+243 characters]",
"sentiment": 0.4767,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts Forecast\n\nBased on [+286 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed estimate data can be found[+344 characters]",
"sentiment": 0.5106,
"highlighted_in": "main_text"
},
{
"highlight": "Based on GuruFocus estimates, the estima[+245 characters]",
"sentiment": 0.8176,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed data can be found on the <[+277 characters]",
"sentiment": 0.5574,
"highlighted_in": "main_text"
},
{
"highlight": "Positive Points\n\n<em>UiPath</em> <em>Inc[+183 characters]",
"sentiment": 0.8481,
"highlighted_in": "main_text"
},
{
"highlight": "<em>UiPath</em> <em>Inc</em> (<em>PATH</[+325 characters]",
"sentiment": 0.8402,
"highlighted_in": "main_text"
},
{
"highlight": "<em>UiPath</em> <em>Inc</em> (<em>PATH</[+198 characters]",
"sentiment": -0.3182,
"highlighted_in": "main_text"
},
{
"highlight": "<em>UiPath</em> (<em>PATH</em>) Sees Price Target Increase Amid Execution Stability | <em>PATH</em> Stock News",
"sentiment": 0.3182,
"highlighted_in": "title"
}
]
},
{
"symbol": "P2AT34.SA",
"name": "UiPath Inc.",
"exchange": null,
"exchange_long": null,
"country": "br",
"type": "equity",
"industry": "Technology",
"match_score": 55.114166,
"sentiment_score": 0.419711,
"highlights": [
{
"highlight": "Bank of America has adjusted its price t[+234 characters]",
"sentiment": 0.4767,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts Forecast\n\nBased on [+277 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed estimate data can be found[+326 characters]",
"sentiment": 0.5106,
"highlighted_in": "main_text"
},
{
"highlight": "Based on GuruFocus estimates, the estima[+236 characters]",
"sentiment": 0.8176,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed data can be found on the <[+259 characters]",
"sentiment": 0.5574,
"highlighted_in": "main_text"
},
{
"highlight": "Positive Points\n\n<em>UiPath</em> <em>Inc[+174 characters]",
"sentiment": 0.8481,
"highlighted_in": "main_text"
},
{
"highlight": "<em>UiPath</em> <em>Inc</em> (PATH) laun[+316 characters]",
"sentiment": 0.8402,
"highlighted_in": "main_text"
},
{
"highlight": "<em>UiPath</em> <em>Inc</em> (PATH) main[+189 characters]",
"sentiment": -0.3182,
"highlighted_in": "main_text"
},
{
"highlight": "<em>UiPath</em> (PATH) Sees Price Target Increase Amid Execution Stability | PATH Stock News",
"sentiment": 0.3182,
"highlighted_in": "title"
}
]
}
]
},
{
"uuid": "588f6ccd-1752-412b-a08b-25b8cf2afe91",
"title": "BofA Adjusts Price Target for Blue Owl Capital (OBDC) Amid Mixed Q1 Results | OBDC Stock News",
"description": "BofA has revised its price target for Blue Owl Capital (OBDC), reducing it from $16.25 to $15.50 while maintaining a Buy rating on the stock. The first quarter",
"keywords": "GuruFocus, Article, News, GuruFocus News, OBDC",
"snippet": "BofA has revised its price target for Blue Owl Capital (OBDC, Financial), reducing it from $16.25 to $15.50 while maintaining a Buy rating on the stock. The fir...",
"url": "https://www.gurufocus.com/news/2900188/bofa-adjusts-price-target-for-blue-owl-capital-obdc-amid-mixed-q1-results-obdc-stock-news",
"image_url": "https://static.gurufocus.com/images/global_logo_twitter_card.png",
"language": "en",
"published_at": "2025-06-01T16:30:43.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "OWL",
"name": "Blue Owl Capital Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Financial Services",
"match_score": 90.30485,
"sentiment_score": 0.254871,
"highlights": [
{
"highlight": "BofA has revised its price target for <e[+282 characters]",
"sentiment": -0.2023,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts Forecast\n\nBased on [+297 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed estimate data can be found[+294 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Based on GuruFocus estimates, the estima[+257 characters]",
"sentiment": 0.8176,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed data can be found on the <[+285 characters]",
"sentiment": 0.5267,
"highlighted_in": "main_text"
},
{
"highlight": "Positive Points\n\n<em>Blue</em> <em>Owl</[+295 characters]",
"sentiment": 0.9153,
"highlighted_in": "main_text"
},
{
"highlight": "BofA Adjusts Price Target for <em>Blue</em> <em>Owl</em> <em>Capital</em> (OBDC) Amid Mixed Q1 Results | OBDC Stock News",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
]
},
{
"uuid": "74d9fc07-5fc2-4109-b0af-f305f8b52fd7",
"title": "Crescent Capital BDC (CCAP) Target Price Lowered by BofA to $17 | CCAP Stock News",
"description": "BofA has revised its price target for Crescent Capital BDC (CCAP), reducing it from $20 to $17 while maintaining a Buy rating on the stock. The decision follows",
"keywords": "GuruFocus, Article, News, GuruFocus News, CCAP",
"snippet": "BofA has revised its price target for Crescent Capital BDC (CCAP, Financial), reducing it from $20 to $17 while maintaining a Buy rating on the stock. The decis...",
"url": "https://www.gurufocus.com/news/2900186/crescent-capital-bdc-ccap-target-price-lowered-by-bofa-to-17-ccap-stock-news",
"image_url": "https://static.gurufocus.com/images/global_logo_twitter_card.png",
"language": "en",
"published_at": "2025-06-01T16:30:26.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "CCAP",
"name": "Crescent Capital BDC, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Financial Services",
"match_score": 118.61191,
"sentiment_score": 0.367522,
"highlights": [
{
"highlight": "BofA has revised its price target for <e[+237 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts Forecast\n\nBased on [+309 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed estimate data can be found[+308 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Based on GuruFocus estimates, the estima[+270 characters]",
"sentiment": 0.7579,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed data can be found on the <[+272 characters]",
"sentiment": 0.5267,
"highlighted_in": "main_text"
},
{
"highlight": "Positive Points\n\n<em>Crescent</em> <em>C[+184 characters]",
"sentiment": 0.7906,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Crescent</em> <em>Capital</em> <em>B[+320 characters]",
"sentiment": 0.9153,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Crescent</em> <em>Capital</em> <em>B[+192 characters]",
"sentiment": 0.7184,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Crescent</em> <em>Capital</em> <em>BDC</em> (CCAP) Target Price Lowered by BofA to $17 | CCAP Stock News",
"sentiment": -0.128,
"highlighted_in": "title"
}
]
}
]
},
{
"uuid": "928e4db0-f461-4ab2-a0f4-0c435ac4d210",
"title": "Sixth Street (TSLX) Receives Price Target Boost from BofA Analyst | TSLX Stock News",
"description": "BofA analyst Derek Hewett has adjusted the price target for Sixth Street (TSLX), raising it from $23 to $24.50 while maintaining a Buy rating on the stock. Desp",
"keywords": "GuruFocus, Article, News, GuruFocus News, TSLX",
"snippet": "BofA analyst Derek Hewett has adjusted the price target for Sixth Street (TSLX, Financial), raising it from $23 to $24.50 while maintaining a Buy rating on the ...",
"url": "https://www.gurufocus.com/news/2900185/sixth-street-tslx-receives-price-target-boost-from-bofa-analyst-tslx-stock-news",
"image_url": "https://static.gurufocus.com/images/global_logo_twitter_card.png",
"language": "en",
"published_at": "2025-06-01T16:30:18.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "TSLX",
"name": "Sixth Street Specialty Lending, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Financial Services",
"match_score": 80.43939,
"sentiment_score": 0.23702,
"highlights": [
{
"highlight": "Wall Street Analysts Forecast\n\nBased on [+329 characters]",
"sentiment": -0.4767,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed estimate data can be found[+347 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Based on GuruFocus estimates, the estima[+287 characters]",
"sentiment": 0.8176,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed data can be found on the <[+99 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Positive Points\n\n<em>Sixth</em> <em>Stre[+218 characters]",
"sentiment": 0.8442,
"highlighted_in": "main_text"
}
]
}
]
}
]
},
{
"uuid": "f6461fed-1f8c-43a1-9129-8685d51c96d7",
"title": "Guardant Health (GH) Reveals Key Insights on Colon Cancer Recurrence | GH Stock News",
"description": "Guardant Health (GH) has unveiled significant findings from an extensive study analyzing circulating tumor DNA (ctDNA) in colon cancer patients before chemother",
"keywords": "GuruFocus, Article, News, GuruFocus News, GH",
"snippet": "Guardant Health (GH, Financial) has unveiled significant findings from an extensive study analyzing circulating tumor DNA (ctDNA) in colon cancer patients befor...",
"url": "https://www.gurufocus.com/news/2900235/guardant-health-gh-reveals-key-insights-on-colon-cancer-recurrence-gh-stock-news",
"image_url": "https://static.gurufocus.com/logos/0C0000BIF0.png?20",
"language": "en",
"published_at": "2025-06-01T21:15:17.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "GH",
"name": "Guardant Health, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 81.9498,
"sentiment_score": 0.003086,
"highlights": [
{
"highlight": "<em>Guardant</em> <em>Health</em> (GH, F[+153 characters]",
"sentiment": -0.7351,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts Forecast\n\nBased on [+294 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed estimate data can be found[+277 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Based on GuruFocus estimates, the estima[+252 characters]",
"sentiment": 0.8176,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed data can be found on the <[+316 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Positive Points\n\n<em>Guardant</em> <em>H[+258 characters]",
"sentiment": 0.872,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Guardant</em> <em>Health</em> (GH) Reveals Key Insights on Colon Cancer Recurrence | GH Stock News",
"sentiment": -0.6597,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "1e8c7310-92d6-4e68-ae13-a7325305897e",
"title": "Trevi Therapeutics to Host Conference Call and Webcast on June 2nd to Share Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough | TRVI",
"description": "Trevi Therapeutics (TRVI) to present topline results from Phase 2b CORAL trial of Haduvio on June 2, 2025. The webcast will provide insights into Haduvi",
"keywords": "GuruFocus, Article, News, GuruFocus News, TRVI",
"snippet": "Trevi Therapeutics (TRVI, Financial) to present topline results from Phase 2b CORAL trial of Haduvio on June 2, 2025.\n\nThe webcast will provide insights into Ha...",
"url": "https://www.gurufocus.com/news/2900234/trevi-therapeutics-to-host-conference-call-and-webcast-on-june-2nd-to-share-topline-results-from-the-phase-2b-coral-trial-of-haduvio-in-patients-with-idiopathic-pulmonary-fibrosis-chronic-cough-trvi",
"image_url": "https://static.gurufocus.com/logos/0C0000BM52.png?20",
"language": "en",
"published_at": "2025-06-01T21:15:10.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "TRVI",
"name": "Trevi Therapeutics, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 55.56231,
"sentiment_score": 0.16835,
"highlights": [
{
"highlight": "<em>Trevi</em> <em>Therapeutics</em> (TR[+337 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "For those unable to attend the live sess[+158 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "For more details, please visit <em>Trevi[+142 characters]",
"sentiment": 0.3774,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Trevi</em> <em>Therapeutics</em> to Host Conference Call and Webcast on June 2nd to Share Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough | TRVI",
"sentiment": 0.296,
"highlighted_in": "title"
}
]
}
],
"similar": [
{
"uuid": "15a6cf4b-f244-4b2a-9e9d-c14ac966f2d8",
"title": "Taiho Oncology and Cullinan Therapeutics Announce Pivotal REZILIENT1 Phase 1/2 Data Published in the Journal of Clinical Oncology",
"description": "PR NewswirePRINCETON, N.J. and CAMBRIDGE, Mass., June 1, 2025\n\n\n\nPRINCETON, N.J. and CAMBRIDGE, Mass., June 1, 2025 /PRNewswire/ -- Taiho Oncology, Inc., and",
"keywords": "GuruFocus, Article, News, PRNewswire, NAS:CGEM",
"snippet": "PRINCETON, N.J. and CAMBRIDGE, Mass., June 1, 2025 /PRNewswire/ -- Taiho Oncology, Inc., and Cullinan Therapeutics, Inc., announced today the publication of pos...",
"url": "https://www.gurufocus.com/news/2900102/taiho-oncology-and-cullinan-therapeutics-announce-pivotal-rezilient1-phase-12-data-published-in-the-journal-of-clinical-oncology",
"image_url": "https://static.gurufocus.com/images/global_logo_twitter_card.png",
"language": "en",
"published_at": "2025-06-01T14:00:03.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "OTSKY",
"name": "Otsuka Holdings Co., Ltd.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 22.985657,
"sentiment_score": 0,
"highlights": [
{
"highlight": "., Ltd. which is part of <em>Otsuka</em>[+335 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "OTSKF",
"name": "Otsuka Holdings Co., Ltd.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 22.98529,
"sentiment_score": 0,
"highlights": [
{
"highlight": "., Ltd. which is part of <em>Otsuka</em>[+335 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "4578.T",
"name": "Otsuka Holdings Co., Ltd.",
"exchange": null,
"exchange_long": null,
"country": "jp",
"type": "equity",
"industry": "Healthcare",
"match_score": 22.983696,
"sentiment_score": 0,
"highlights": [
{
"highlight": "., Ltd. which is part of <em>Otsuka</em>[+335 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
}
]
},
{
"uuid": "e8318e12-2f0e-4b04-b325-d41701ebe10e",
"title": "IMFINZI® (durvalumab) regimen reduced risk of progression, recurrence or death by 29% in early-stage gastric cancer vs. chemotherapy alone in MATTERHORN Phase III trial",
"description": "Positive results from the MATTERHORN Phase III trial showed perioperative treatment with AstraZeneca's IMFINZI®(durvalumab) in combination with standard-of-ca",
"keywords": "GuruFocus, Article, News, Business Wire, NAS:AZN",
"snippet": "Positive results from the MATTERHORN Phase III trial showed perioperative treatment with AstraZeneca’s IMFINZI®(durvalumab) in combination with standard-of-c...",
"url": "https://www.gurufocus.com/news/2900098/imfinzi-durvalumab-regimen-reduced-risk-of-progression-recurrence-or-death-by-29-in-earlystage-gastric-cancer-vs-chemotherapy-alone-in-matterhorn-phase-iii-trial",
"image_url": "https://static.gurufocus.com/images/global_logo_twitter_card.png",
"language": "en",
"published_at": "2025-06-01T14:00:02.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "MRK",
"name": "Merck & Co., Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 4.225693,
"sentiment_score": 0,
"highlights": [
{
"highlight": "Olaparib is developed and commercialized[+105 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "AZN",
"name": "AstraZeneca PLC",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 12.743948,
"sentiment_score": -0.24892,
"highlights": [
{
"highlight": "You may report side effects related to <[+29 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> in GI cancers\n\n<em>[+157 characters]",
"sentiment": -0.3818,
"highlighted_in": "main_text"
},
{
"highlight": "Olaparib is developed and commercialized[+87 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> is advancing multip[+129 characters]",
"sentiment": -0.4019,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> in immuno-oncology [+141 characters]",
"sentiment": 0.4588,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> in oncology\n\n<em>As[+314 characters]",
"sentiment": -0.8375,
"highlighted_in": "main_text"
},
{
"highlight": "It is through persistent innovation that[+315 characters]",
"sentiment": -0.7845,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em>\n\n<em>AstraZeneca</e[+271 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> <em>PLC</em>. Inves[+275 characters]",
"sentiment": -0.5423,
"highlighted_in": "main_text"
},
{
"highlight": "Janjigian provides consulting and adviso[+165 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "AZNCF",
"name": "AstraZeneca PLC",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 12.74382,
"sentiment_score": -0.24892,
"highlights": [
{
"highlight": "You may report side effects related to <[+29 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> in GI cancers\n\n<em>[+157 characters]",
"sentiment": -0.3818,
"highlighted_in": "main_text"
},
{
"highlight": "Olaparib is developed and commercialized[+87 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> is advancing multip[+129 characters]",
"sentiment": -0.4019,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> in immuno-oncology [+141 characters]",
"sentiment": 0.4588,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> in oncology\n\n<em>As[+314 characters]",
"sentiment": -0.8375,
"highlighted_in": "main_text"
},
{
"highlight": "It is through persistent innovation that[+315 characters]",
"sentiment": -0.7845,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em>\n\n<em>AstraZeneca</e[+271 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> <em>PLC</em>. Inves[+275 characters]",
"sentiment": -0.5423,
"highlighted_in": "main_text"
},
{
"highlight": "Janjigian provides consulting and adviso[+165 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "ZEG.DE",
"name": "AstraZeneca PLC",
"exchange": null,
"exchange_long": null,
"country": "de",
"type": "equity",
"industry": "Healthcare",
"match_score": 12.743676,
"sentiment_score": -0.24892,
"highlights": [
{
"highlight": "You may report side effects related to <[+29 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> in GI cancers\n\n<em>[+157 characters]",
"sentiment": -0.3818,
"highlighted_in": "main_text"
},
{
"highlight": "Olaparib is developed and commercialized[+87 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> is advancing multip[+129 characters]",
"sentiment": -0.4019,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> in immuno-oncology [+141 characters]",
"sentiment": 0.4588,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> in oncology\n\n<em>As[+314 characters]",
"sentiment": -0.8375,
"highlighted_in": "main_text"
},
{
"highlight": "It is through persistent innovation that[+315 characters]",
"sentiment": -0.7845,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em>\n\n<em>AstraZeneca</e[+271 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> <em>PLC</em>. Inves[+275 characters]",
"sentiment": -0.5423,
"highlighted_in": "main_text"
},
{
"highlight": "Janjigian provides consulting and adviso[+165 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "6MK.DE",
"name": "Merck & Co., Inc.",
"exchange": null,
"exchange_long": null,
"country": "de",
"type": "equity",
"industry": "Healthcare",
"match_score": 4.225706,
"sentiment_score": 0,
"highlights": [
{
"highlight": "Olaparib is developed and commercialized[+105 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "MRK.PA",
"name": "Merck & Co., Inc.",
"exchange": null,
"exchange_long": null,
"country": "fr",
"type": "equity",
"industry": "Healthcare",
"match_score": 4.225678,
"sentiment_score": 0,
"highlights": [
{
"highlight": "Olaparib is developed and commercialized[+105 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "AZNN.MX",
"name": "AstraZeneca PLC",
"exchange": null,
"exchange_long": null,
"country": "mx",
"type": "equity",
"industry": "Healthcare",
"match_score": 12.742851,
"sentiment_score": -0.24892,
"highlights": [
{
"highlight": "You may report side effects related to <[+29 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> in GI cancers\n\n<em>[+157 characters]",
"sentiment": -0.3818,
"highlighted_in": "main_text"
},
{
"highlight": "Olaparib is developed and commercialized[+87 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> is advancing multip[+129 characters]",
"sentiment": -0.4019,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> in immuno-oncology [+141 characters]",
"sentiment": 0.4588,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> in oncology\n\n<em>As[+314 characters]",
"sentiment": -0.8375,
"highlighted_in": "main_text"
},
{
"highlight": "It is through persistent innovation that[+315 characters]",
"sentiment": -0.7845,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em>\n\n<em>AstraZeneca</e[+271 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> <em>PLC</em>. Inves[+275 characters]",
"sentiment": -0.5423,
"highlighted_in": "main_text"
},
{
"highlight": "Janjigian provides consulting and adviso[+165 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "MRK.MX",
"name": "Merck & Co., Inc.",
"exchange": null,
"exchange_long": null,
"country": "mx",
"type": "equity",
"industry": "Healthcare",
"match_score": 4.225326,
"sentiment_score": 0,
"highlights": [
{
"highlight": "Olaparib is developed and commercialized[+105 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "AZN.L",
"name": "AstraZeneca PLC",
"exchange": null,
"exchange_long": null,
"country": "gb",
"type": "equity",
"industry": "Healthcare",
"match_score": 12.742768,
"sentiment_score": -0.24892,
"highlights": [
{
"highlight": "You may report side effects related to <[+29 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> in GI cancers\n\n<em>[+157 characters]",
"sentiment": -0.3818,
"highlighted_in": "main_text"
},
{
"highlight": "Olaparib is developed and commercialized[+87 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> is advancing multip[+129 characters]",
"sentiment": -0.4019,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> in immuno-oncology [+141 characters]",
"sentiment": 0.4588,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> in oncology\n\n<em>As[+314 characters]",
"sentiment": -0.8375,
"highlighted_in": "main_text"
},
{
"highlight": "It is through persistent innovation that[+315 characters]",
"sentiment": -0.7845,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em>\n\n<em>AstraZeneca</e[+271 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> <em>PLC</em>. Inves[+275 characters]",
"sentiment": -0.5423,
"highlighted_in": "main_text"
},
{
"highlight": "Janjigian provides consulting and adviso[+165 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "0A4J.L",
"name": "AstraZeneca PLC",
"exchange": null,
"exchange_long": null,
"country": "gb",
"type": "equity",
"industry": "N/A",
"match_score": 12.74267,
"sentiment_score": -0.24892,
"highlights": [
{
"highlight": "You may report side effects related to <[+29 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> in GI cancers\n\n<em>[+157 characters]",
"sentiment": -0.3818,
"highlighted_in": "main_text"
},
{
"highlight": "Olaparib is developed and commercialized[+87 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> is advancing multip[+129 characters]",
"sentiment": -0.4019,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> in immuno-oncology [+141 characters]",
"sentiment": 0.4588,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> in oncology\n\n<em>As[+314 characters]",
"sentiment": -0.8375,
"highlighted_in": "main_text"
},
{
"highlight": "It is through persistent innovation that[+315 characters]",
"sentiment": -0.7845,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em>\n\n<em>AstraZeneca</e[+271 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> <em>PLC</em>. Inves[+275 characters]",
"sentiment": -0.5423,
"highlighted_in": "main_text"
},
{
"highlight": "Janjigian provides consulting and adviso[+165 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "MRKD.BA",
"name": "MERCK & CO INC",
"exchange": null,
"exchange_long": null,
"country": "ar",
"type": "equity",
"industry": "N/A",
"match_score": 4.225332,
"sentiment_score": 0,
"highlights": [
{
"highlight": "Olaparib is developed and commercialized[+105 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "MRK.SN",
"name": "Merck & Co., Inc.",
"exchange": null,
"exchange_long": null,
"country": "cl",
"type": "equity",
"industry": "Healthcare",
"match_score": 4.225323,
"sentiment_score": 0,
"highlights": [
{
"highlight": "Olaparib is developed and commercialized[+105 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
}
]
}
]
},
{
"uuid": "229decea-ea71-477f-b2b4-7ef6bbbf5dd8",
"title": "GILD: Gilead's Trodelvy Shows Significant Benefit in Breast Cancer Study | GILD Stock News",
"description": "Gilead Sciences (GILD) has announced promising results from a pivotal study involving Trodelvy and Keytruda in treating PD-L1+ metastatic triple-negative breast",
"keywords": "GuruFocus, Article, News, GuruFocus News, GILD",
"snippet": "Gilead Sciences (GILD, Financial) has announced promising results from a pivotal study involving Trodelvy and Keytruda in treating PD-L1+ metastatic triple-nega...",
"url": "https://www.gurufocus.com/news/2900233/gild-gileads-trodelvy-shows-significant-benefit-in-breast-cancer-study-gild-stock-news",
"image_url": "https://static.gurufocus.com/logos/0C000007VR.png?20",
"language": "en",
"published_at": "2025-06-01T21:00:37.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "GILD",
"name": "Gilead Sciences, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 58.57052,
"sentiment_score": -0.06848,
"highlights": [
{
"highlight": "<em>Gilead</em> <em>Sciences</em> (GILD,[+327 characters]",
"sentiment": -0.8271,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts Forecast\n\nBased on [+298 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed estimate data can be found[+281 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Based on GuruFocus estimates, the estima[+257 characters]",
"sentiment": 0.7579,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed data can be found on the <[+66 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
}
],
"similar": [
{
"uuid": "e6cc881f-ba9b-4eb0-85ba-e82f8acfae6e",
"title": "Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting | REPL Stock News",
"description": "Replimune's RP1 plus nivolumab shows a 32.9% response rate in anti-PD1 failed melanoma patients. Higher response rates achieved with deep/visceral injec",
"keywords": "GuruFocus, Article, News, GuruFocus News, REPL",
"snippet": "Replimune's RP1 plus nivolumab shows a 32.9% response rate in anti-PD1 failed melanoma patients.\n\nHigher response rates achieved with deep/visceral injections (...",
"url": "https://www.gurufocus.com/news/2900112/replimune-presents-new-analyses-from-the-ignyte-study-of-rp1-plus-nivolumab-in-antipd1-failed-melanoma-at-the-2025-american-society-of-clinical-oncology-asco-annual-meeting-repl-stock-news",
"image_url": "https://static.gurufocus.com/logos/0C0000BHIM.png?20",
"language": "en",
"published_at": "2025-06-01T15:15:09.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "REPL",
"name": "Replimune Group, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 46.33197,
"sentiment_score": -0.05435,
"highlights": [
{
"highlight": "<em>Replimune</em> <em>Group</em>, <em>I[+303 characters]",
"sentiment": 0.4019,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Replimune</em> Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting | REPL Stock News",
"sentiment": -0.5106,
"highlighted_in": "title"
}
]
}
]
}
]
},
{
"uuid": "2fee0c00-8192-4b43-ab30-36bd3455b570",
"title": "Leonardo S.P.A's (FINMF) Strategic Moves in Aerospace and Defense",
"description": "Quick Summary:\n Leonardo S.P.A (FINMF) launches a New Space Division to expand its satellite capabilities. The firm projects mid-teens growth in profits a",
"keywords": "GuruFocus, Article, News, GuruFocus News, FINMF",
"snippet": "Quick Summary:\n\nLeonardo S.P.A (FINMF, Financial) launches a New Space Division to expand its satellite capabilities.\n\nThe firm projects mid-teens growth in pro...",
"url": "https://www.gurufocus.com/news/2900223/leonardo-spas-finmf-strategic-moves-in-aerospace-and-defense",
"image_url": "https://static.gurufocus.com/logos/0C00000QFH.png?20",
"language": "en",
"published_at": "2025-06-01T20:55:44.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "FINMY",
"name": "Leonardo S.p.a.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Industrials",
"match_score": 48.41721,
"sentiment_score": 0.733867,
"highlights": [
{
"highlight": "Quick Summary:\n\n<em>Leonardo</em> <em>S.[+245 characters]",
"sentiment": 0.9001,
"highlighted_in": "main_text"
},
{
"highlight": "Leonardo S.P.A's Strategic Expansion\n\nIt[+323 characters]",
"sentiment": 0.3612,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Leonardo</em> <em>S.P.A</em> anticip[+272 characters]",
"sentiment": 0.9403,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "FINMF",
"name": "Leonardo S.p.a.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Industrials",
"match_score": 100.68573,
"sentiment_score": 0.5824,
"highlights": [
{
"highlight": "Quick Summary:\n\n<em>Leonardo</em> <em>S.[+254 characters]",
"sentiment": 0.9001,
"highlighted_in": "main_text"
},
{
"highlight": "Leonardo S.P.A's Strategic Expansion\n\nIt[+332 characters]",
"sentiment": 0.3612,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Leonardo</em> <em>S.P.A</em> anticip[+272 characters]",
"sentiment": 0.9403,
"highlighted_in": "main_text"
},
{
"highlight": "Leonardo S.P.A's (<em>FINMF</em>) Strategic Moves in Aerospace and Defense",
"sentiment": 0.128,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "465f611a-b3a4-4082-bc1d-cbb960c94b56",
"title": "Seagate Technology (STX) Surges Over 29% on Revenue Guidance Boost and Share Buyback",
"description": "Key Takeaways:\n Seagate Technology (STX) shares surged by 29.56% in May, driven by revised upbeat revenue guidance and AI storage demand. The company anno",
"keywords": "GuruFocus, Article, News, GuruFocus News, STX",
"snippet": "Key Takeaways:\n\nSeagate Technology (STX, Financial) shares surged by 29.56% in May, driven by revised upbeat revenue guidance and AI storage demand.\n\nThe compan...",
"url": "https://www.gurufocus.com/news/2900222/seagate-technology-stx-surges-over-29-on-revenue-guidance-boost-and-share-buyback",
"image_url": "https://static.gurufocus.com/logos/0C000008YL.png?20",
"language": "en",
"published_at": "2025-06-01T20:55:36.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "STX",
"name": "Seagate Technology plc",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Technology",
"match_score": 70.54289,
"sentiment_score": 0.454671,
"highlights": [
{
"highlight": "Key Takeaways:\n\n<em>Seagate</em> <em>Tec[+228 characters]",
"sentiment": 0.7906,
"highlighted_in": "main_text"
},
{
"highlight": "Seagate's Stock Surge: Understanding the[+151 characters]",
"sentiment": 0.7964,
"highlighted_in": "main_text"
},
{
"highlight": "Analyst Price Targets and Recommendation[+228 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "Investors can explore more detailed esti[+260 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Assessing the GF Value and Future Outloo[+224 characters]",
"sentiment": 0.6369,
"highlighted_in": "main_text"
},
{
"highlight": "More comprehensive data is available on [+220 characters]",
"sentiment": 0.6326,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Seagate</em> <em>Technology</em> (STX) Surges Over 29% on Revenue Guidance Boost and Share Buyback",
"sentiment": 0.5994,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "b82f48e2-632c-4595-80d1-ae82cd06d9e6",
"title": "JPMorgan's (JPM) Dimon Highlights U.S. Fiscal Concerns",
"description": "Key Takeaways:\n JPMorgan CEO warns of potential risks in the U.S. bond market due to increasing fiscal debt. Analysts predict a modest upside potential fo",
"keywords": "GuruFocus, Article, News, GuruFocus News, JPM",
"snippet": "Key Takeaways:\n\nJPMorgan CEO warns of potential risks in the U.S. bond market due to increasing fiscal debt.\n\nAnalysts predict a modest upside potential for JPM...",
"url": "https://www.gurufocus.com/news/2900221/jpmorgans-jpm-dimon-highlights-us-fiscal-concerns",
"image_url": "https://static.gurufocus.com/logos/0C00000BMT.png?20",
"language": "en",
"published_at": "2025-06-01T20:55:20.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "JPM",
"name": "JPMorgan Chase & Co.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Financial Services",
"match_score": 48.712425,
"sentiment_score": 0.165475,
"highlights": [
{
"highlight": "Wall Street Analysts Forecast for JPMorg[+313 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "Investors can explore more detailed esti[+307 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "GuruFocus Valuation Insights\n\nAccording [+315 characters]",
"sentiment": 0.6249,
"highlighted_in": "main_text"
},
{
"highlight": "For more comprehensive data, visit the <[+65 characters]",
"sentiment": 0.3102,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "d20c8b1b-85a4-4557-9bd2-fe1ac6c303e8",
"title": "ROSEN, GLOBAL INVESTOR COUNSEL, Encourages DoubleVerify Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action -- DV",
"description": "NEW YORK, June 01, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf",
"keywords": "GuruFocus, Article, News, Marketwired, DV",
"snippet": "NEW YORK, June 01, 2025 (GLOBE NEWSWIRE) --\n\nWHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of...",
"url": "https://www.gurufocus.com/news/2900217/rosen-global-investor-counsel-encourages-doubleverify-holdings-inc-investors-to-secure-counsel-before-important-deadline-in-securities-class-action-dv",
"image_url": "https://static.gurufocus.com/images/global_logo_twitter_card.png",
"language": "en",
"published_at": "2025-06-01T20:00:02.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "DV",
"name": "DoubleVerify Holdings, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Services",
"match_score": 99.13888,
"sentiment_score": 0.5628,
"highlights": [
{
"highlight": "NEW YORK, June 01, 2025 (GLOBE NEWSWIRE)[+308 characters]",
"sentiment": 0.3182,
"highlighted_in": "main_text"
},
{
"highlight": "ROSEN, GLOBAL INVESTOR COUNSEL, Encourages <em>DoubleVerify</em> <em>Holdings</em>, <em>Inc</em>. Investors to Secure Counsel Before Important Deadline in Securities Class Action -- DV",
"sentiment": 0.8074,
"highlighted_in": "title"
}
]
}
],
"similar": [
{
"uuid": "aeeaa822-b7d5-479a-b4ab-16114b6930f4",
"title": "INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in DoubleVerify Holdings, Inc. of Class Action Lawsuit and Upcoming Deadlines - DV",
"description": "PR NewswireNEW YORK, June 1, 2025\n\n\n\nNEW YORK, June 1, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against DoubleV",
"keywords": "GuruFocus, Article, News, PRNewswire, NYSE:DV",
"snippet": "NEW YORK, June 1, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against DoubleVerify Holdings, Inc. (\"DoubleVerify\" or...",
"url": "https://www.gurufocus.com/news/2900120/investor-alert-pomerantz-law-firm-reminds-investors-with-losses-on-their-investment-in-doubleverify-holdings-incof-class-action-lawsuit-and-upcoming-deadlines-dv-",
"image_url": "https://static.gurufocus.com/images/global_logo_twitter_card.png",
"language": "en",
"published_at": "2025-06-01T16:00:03.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "DV",
"name": "DoubleVerify Holdings, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Services",
"match_score": 106.05641,
"sentiment_score": -0.025933,
"highlights": [
{
"highlight": "NEW YORK, June 1, 2025 /PRNewswire/ -- P[+324 characters]",
"sentiment": -0.2263,
"highlighted_in": "main_text"
},
{
"highlight": "CONTACT:\n\nDanielle Peyton\n\nPomerantz LLP[+337 characters]",
"sentiment": 0.3182,
"highlighted_in": "main_text"
},
{
"highlight": "INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in <em>DoubleVerify</em> <em>Holdings</em>, <em>Inc</em>. of Class Action Lawsuit and Upcoming Deadlines - DV",
"sentiment": -0.1697,
"highlighted_in": "title"
}
]
}
]
}
]
},
{
"uuid": "66855df9-db31-44a8-acac-a0b8e2c54427",
"title": "Viatris Deadline: VTRS Investors with Losses in Excess of $100K Have Opportunity to Lead Viatris Inc. Securities Fraud Lawsuit",
"description": "PR NewswireNEW YORK, June 1, 2025\n\n\n\nNEW YORK, June 1, 2025 /PRNewswire/ --",
"keywords": "GuruFocus, Article, News, PRNewswire, NAS:VTRS",
"snippet": "NEW YORK, June 1, 2025 /PRNewswire/ --\n\nWhy: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Viatris Inc. (NASDAQ: VTRS) ...",
"url": "https://www.gurufocus.com/news/2900218/viatris-deadline-vtrs-investors-with-losses-in-excess-of-100k-have-opportunity-to-lead-viatris-inc-securities-fraud-lawsuit",
"image_url": "https://static.gurufocus.com/images/global_logo_twitter_card.png",
"language": "en",
"published_at": "2025-06-01T20:00:02.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "VTRSV",
"name": "Viatris Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "N/A",
"match_score": 82.76165,
"sentiment_score": -0.08812,
"highlights": [
{
"highlight": "NEW YORK, June 1, 2025 /PRNewswire/ --\n\n[+281 characters]",
"sentiment": 0.4588,
"highlighted_in": "main_text"
},
{
"highlight": "So what: If you purchased <em>Viatris</e[+267 characters]",
"sentiment": 0.6705,
"highlighted_in": "main_text"
},
{
"highlight": "Details of the case: According to the la[+165 characters]",
"sentiment": -0.6369,
"highlighted_in": "main_text"
},
{
"highlight": "Defendants' statements, albeit made mont[+319 characters]",
"sentiment": 0.0772,
"highlighted_in": "main_text"
},
{
"highlight": "Defendants routinely referred to the imp[+74 characters]",
"sentiment": -0.34,
"highlighted_in": "main_text"
},
{
"highlight": "Further, defendants provided these discl[+230 characters]",
"sentiment": -0.5859,
"highlighted_in": "main_text"
},
{
"highlight": "Defendants further notably failed to dis[+297 characters]",
"sentiment": -0.4767,
"highlighted_in": "main_text"
},
{
"highlight": "Such statements, absent these material f[+300 characters]",
"sentiment": -0.2023,
"highlighted_in": "main_text"
},
{
"highlight": "The Rosen Law Firm, P.A.\n\n275 Madison Av[+382 characters]",
"sentiment": 0.6808,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Viatris</em> Deadline: VTRS Investors with Losses in Excess of $100K Have Opportunity to Lead <em>Viatris</em> <em>Inc</em>. Securities Fraud Lawsuit",
"sentiment": -0.5267,
"highlighted_in": "title"
}
]
},
{
"symbol": "VTRS",
"name": "Viatris Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 94.034805,
"sentiment_score": -0.08812,
"highlights": [
{
"highlight": "NEW YORK, June 1, 2025 /PRNewswire/ --\n\n[+299 characters]",
"sentiment": 0.4588,
"highlighted_in": "main_text"
},
{
"highlight": "So what: If you purchased <em>Viatris</e[+267 characters]",
"sentiment": 0.6705,
"highlighted_in": "main_text"
},
{
"highlight": "Details of the case: According to the la[+165 characters]",
"sentiment": -0.6369,
"highlighted_in": "main_text"
},
{
"highlight": "Defendants' statements, albeit made mont[+319 characters]",
"sentiment": 0.0772,
"highlighted_in": "main_text"
},
{
"highlight": "Defendants routinely referred to the imp[+74 characters]",
"sentiment": -0.34,
"highlighted_in": "main_text"
},
{
"highlight": "Further, defendants provided these discl[+230 characters]",
"sentiment": -0.5859,
"highlighted_in": "main_text"
},
{
"highlight": "Defendants further notably failed to dis[+297 characters]",
"sentiment": -0.4767,
"highlighted_in": "main_text"
},
{
"highlight": "Such statements, absent these material f[+300 characters]",
"sentiment": -0.2023,
"highlighted_in": "main_text"
},
{
"highlight": "The Rosen Law Firm, P.A.\n\n275 Madison Av[+382 characters]",
"sentiment": 0.6808,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Viatris</em> Deadline: VTRS Investors with Losses in Excess of $100K Have Opportunity to Lead <em>Viatris</em> <em>Inc</em>. Securities Fraud Lawsuit",
"sentiment": -0.5267,
"highlighted_in": "title"
}
]
}
],
"similar": [
{
"uuid": "5904808a-aef0-4032-8da1-628dbdab398a",
"title": "INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Viatris Inc. of Class Action Lawsuit and Upcoming Deadlines - VTRS",
"description": "PR NewswireNEW YORK, June 1, 2025\n\n\n\nNEW YORK, June 1, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Viatris",
"keywords": "GuruFocus, Article, News, PRNewswire, NAS:VTRS",
"snippet": "NEW YORK, June 1, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Viatris, Inc. (\"Viatris\" or the \"Company\") (NA...",
"url": "https://www.gurufocus.com/news/2900135/investor-alert-pomerantz-law-firm-reminds-investors-with-losses-on-their-investment-in-viatris-inc-of-class-action-lawsuit-and-upcoming-deadlines-vtrs",
"image_url": "https://static.gurufocus.com/images/global_logo_twitter_card.png",
"language": "en",
"published_at": "2025-06-01T16:00:05.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "VTRSV",
"name": "Viatris Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "N/A",
"match_score": 64.98822,
"sentiment_score": 0.103933,
"highlights": [
{
"highlight": "NEW YORK, June 1, 2025 /PRNewswire/ -- P[+292 characters]",
"sentiment": -0.2263,
"highlighted_in": "main_text"
},
{
"highlight": "The class action concerns whether <em>Vi[+311 characters]",
"sentiment": 0.5267,
"highlighted_in": "main_text"
},
{
"highlight": "[Click here for information about joinin[+299 characters]",
"sentiment": 0.2263,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Viatris</em> also provided an update[+126 characters]",
"sentiment": -0.0516,
"highlighted_in": "main_text"
},
{
"highlight": "CONTACT:\n\nDanielle Peyton\n\nPomerantz LLP[+334 characters]",
"sentiment": 0.3182,
"highlighted_in": "main_text"
},
{
"highlight": "INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in <em>Viatris</em> <em>Inc</em>. of Class Action Lawsuit and Upcoming Deadlines - VTRS",
"sentiment": -0.1697,
"highlighted_in": "title"
}
]
},
{
"symbol": "VTRS",
"name": "Viatris Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 79.63095,
"sentiment_score": 0.103933,
"highlights": [
{
"highlight": "NEW YORK, June 1, 2025 /PRNewswire/ -- P[+310 characters]",
"sentiment": -0.2263,
"highlighted_in": "main_text"
},
{
"highlight": "The class action concerns whether <em>Vi[+311 characters]",
"sentiment": 0.5267,
"highlighted_in": "main_text"
},
{
"highlight": "[Click here for information about joinin[+299 characters]",
"sentiment": 0.2263,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Viatris</em> also provided an update[+126 characters]",
"sentiment": -0.0516,
"highlighted_in": "main_text"
},
{
"highlight": "CONTACT:\n\nDanielle Peyton\n\nPomerantz LLP[+334 characters]",
"sentiment": 0.3182,
"highlighted_in": "main_text"
},
{
"highlight": "INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in <em>Viatris</em> <em>Inc</em>. of Class Action Lawsuit and Upcoming Deadlines - VTRS",
"sentiment": -0.1697,
"highlighted_in": "title"
}
]
},
{
"symbol": "VIA.DE",
"name": "Viatris Inc.",
"exchange": null,
"exchange_long": null,
"country": "de",
"type": "equity",
"industry": "Healthcare",
"match_score": 60.727684,
"sentiment_score": 0.103933,
"highlights": [
{
"highlight": "NEW YORK, June 1, 2025 /PRNewswire/ -- P[+292 characters]",
"sentiment": -0.2263,
"highlighted_in": "main_text"
},
{
"highlight": "The class action concerns whether <em>Vi[+311 characters]",
"sentiment": 0.5267,
"highlighted_in": "main_text"
},
{
"highlight": "[Click here for information about joinin[+299 characters]",
"sentiment": 0.2263,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Viatris</em> also provided an update[+126 characters]",
"sentiment": -0.0516,
"highlighted_in": "main_text"
},
{
"highlight": "CONTACT:\n\nDanielle Peyton\n\nPomerantz LLP[+334 characters]",
"sentiment": 0.3182,
"highlighted_in": "main_text"
},
{
"highlight": "INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in <em>Viatris</em> <em>Inc</em>. of Class Action Lawsuit and Upcoming Deadlines - VTRS",
"sentiment": -0.1697,
"highlighted_in": "title"
}
]
},
{
"symbol": "VTRS.MX",
"name": "Viatris Inc.",
"exchange": null,
"exchange_long": null,
"country": "mx",
"type": "equity",
"industry": "N/A",
"match_score": 60.725212,
"sentiment_score": 0.103933,
"highlights": [
{
"highlight": "NEW YORK, June 1, 2025 /PRNewswire/ -- P[+292 characters]",
"sentiment": -0.2263,
"highlighted_in": "main_text"
},
{
"highlight": "The class action concerns whether <em>Vi[+311 characters]",
"sentiment": 0.5267,
"highlighted_in": "main_text"
},
{
"highlight": "[Click here for information about joinin[+299 characters]",
"sentiment": 0.2263,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Viatris</em> also provided an update[+126 characters]",
"sentiment": -0.0516,
"highlighted_in": "main_text"
},
{
"highlight": "CONTACT:\n\nDanielle Peyton\n\nPomerantz LLP[+334 characters]",
"sentiment": 0.3182,
"highlighted_in": "main_text"
},
{
"highlight": "INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in <em>Viatris</em> <em>Inc</em>. of Class Action Lawsuit and Upcoming Deadlines - VTRS",
"sentiment": -0.1697,
"highlighted_in": "title"
}
]
}
]
},
{
"uuid": "b7bc6fef-87b3-4943-9ca6-2b49849e7351",
"title": "ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Digimarc Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action -- DMRC",
"description": "NEW YORK, June 01, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Digimarc Corporation",
"keywords": "GuruFocus, Article, News, Marketwired, DMRC",
"snippet": "NEW YORK, June 01, 2025 (GLOBE NEWSWIRE) --\n\nWHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Digimarc Corporation ( ...",
"url": "https://www.gurufocus.com/news/2900092/rosen-top-ranked-investor-counsel-encourages-digimarc-corporation-investors-to-secure-counsel-before-important-deadline-in-securities-class-action-dmrc",
"image_url": "https://static.gurufocus.com/images/global_logo_twitter_card.png",
"language": "en",
"published_at": "2025-06-01T14:00:02.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "DMRC",
"name": "Digimarc Corporation",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Technology",
"match_score": 77.828125,
"sentiment_score": 0.22862,
"highlights": [
{
"highlight": "NEW YORK, June 01, 2025 (GLOBE NEWSWIRE)[+288 characters]",
"sentiment": 0.4588,
"highlighted_in": "main_text"
},
{
"highlight": "SO WHAT: If you purchased <em>Digimarc</[+269 characters]",
"sentiment": 0.6705,
"highlighted_in": "main_text"
},
{
"highlight": "DETAILS OF THE CASE: According to the la[+325 characters]",
"sentiment": -0.7845,
"highlighted_in": "main_text"
},
{
"highlight": "To join the <em>Digimarc</em> class acti[+305 characters]",
"sentiment": -0.0717,
"highlighted_in": "main_text"
},
{
"highlight": "ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages <em>Digimarc</em> <em>Corporation</em> Investors to Secure Counsel Before Important Deadline in Securities Class Action -- DMRC",
"sentiment": 0.87,
"highlighted_in": "title"
}
]
}
]
},
{
"uuid": "625fcccd-0cf8-4f21-b36e-bbddfcb81526",
"title": "ROSEN, LEADING INVESTOR COUNSEL, Encourages West Pharmaceutical Services, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action -- WST",
"description": "NEW YORK, June 01, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of West Pharmaceutica",
"keywords": "GuruFocus, Article, News, Marketwired, WST",
"snippet": "NEW YORK, June 01, 2025 (GLOBE NEWSWIRE) --\n\nWHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of West Pharmaceutical S...",
"url": "https://www.gurufocus.com/news/2900095/rosen-leading-investor-counsel-encourages-west-pharmaceutical-services-inc-investors-to-secure-counsel-before-important-deadline-in-securities-class-action-wst",
"image_url": "https://static.gurufocus.com/images/global_logo_twitter_card.png",
"language": "en",
"published_at": "2025-06-01T14:00:02.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "WST",
"name": "West Pharmaceutical Services, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 118.08943,
"sentiment_score": 0.7099,
"highlights": [
{
"highlight": "NEW YORK, June 01, 2025 (GLOBE NEWSWIRE)[+328 characters]",
"sentiment": 0.6124,
"highlighted_in": "main_text"
},
{
"highlight": "ROSEN, LEADING INVESTOR COUNSEL, Encourages <em>West</em> <em>Pharmaceutical</em> <em>Services</em>, <em>Inc</em>. Investors to Secure Counsel Before Important Deadline in Securities Class Action -- WST",
"sentiment": 0.8074,
"highlighted_in": "title"
}
]
}
]
},
{
"uuid": "d17dbe95-fcac-486e-b6fd-8c857c5c008f",
"title": "CAR Investors Have Opportunity to Lead Avis Budget Group, Inc. Securities Fraud Lawsuit",
"description": "PR NewswireNEW YORK, June 1, 2025\n\n\n\nNEW YORK, June 1, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securitie",
"keywords": "GuruFocus, Article, News, PRNewswire, NAS:CAR",
"snippet": "NEW YORK, June 1, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Avis Budget Group, Inc. (NASDAQ: C...",
"url": "https://www.gurufocus.com/news/2900075/car-investors-have-opportunity-to-lead-avis-budget-group-inc-securities-fraud-lawsuit",
"image_url": "https://static.gurufocus.com/images/global_logo_twitter_card.png",
"language": "en",
"published_at": "2025-06-01T12:00:03.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "CAR",
"name": "Avis Budget Group, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Industrials",
"match_score": 135.88943,
"sentiment_score": 0.037414,
"highlights": [
{
"highlight": "NEW YORK, June 1, 2025 /PRNewswire/ -- R[+325 characters]",
"sentiment": 0.4588,
"highlighted_in": "main_text"
},
{
"highlight": "So What: If you purchased <em>Avis</em> [+293 characters]",
"sentiment": 0.6705,
"highlighted_in": "main_text"
},
{
"highlight": "Details of the case: According to the la[+330 characters]",
"sentiment": -0.6124,
"highlighted_in": "main_text"
},
{
"highlight": "of Avis Budget's vehicles in the America[+333 characters]",
"sentiment": -0.7579,
"highlighted_in": "main_text"
},
{
"highlight": "To join the <em>Avis</em> <em>Budget</em[+300 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "The Rosen Law Firm, P.A.\n\n275 Madison Av[+353 characters]",
"sentiment": 0.6808,
"highlighted_in": "main_text"
},
{
"highlight": "CAR Investors Have Opportunity to Lead <em>Avis</em> <em>Budget</em> <em>Group</em>, <em>Inc</em>. Securities Fraud Lawsuit",
"sentiment": -0.1779,
"highlighted_in": "title"
}
]
},
{
"symbol": "CAR.MX",
"name": "Avis Budget Group, Inc.",
"exchange": null,
"exchange_long": null,
"country": "mx",
"type": "equity",
"industry": "Industrials",
"match_score": 125.64248,
"sentiment_score": 0.037414,
"highlights": [
{
"highlight": "NEW YORK, June 1, 2025 /PRNewswire/ -- R[+307 characters]",
"sentiment": 0.4588,
"highlighted_in": "main_text"
},
{
"highlight": "So What: If you purchased <em>Avis</em> [+293 characters]",
"sentiment": 0.6705,
"highlighted_in": "main_text"
},
{
"highlight": "Details of the case: According to the la[+330 characters]",
"sentiment": -0.6124,
"highlighted_in": "main_text"
},
{
"highlight": "of Avis Budget's vehicles in the America[+333 characters]",
"sentiment": -0.7579,
"highlighted_in": "main_text"
},
{
"highlight": "To join the <em>Avis</em> <em>Budget</em[+300 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "The Rosen Law Firm, P.A.\n\n275 Madison Av[+353 characters]",
"sentiment": 0.6808,
"highlighted_in": "main_text"
},
{
"highlight": "CAR Investors Have Opportunity to Lead <em>Avis</em> <em>Budget</em> <em>Group</em>, <em>Inc</em>. Securities Fraud Lawsuit",
"sentiment": -0.1779,
"highlighted_in": "title"
}
]
},
{
"symbol": "0HK4.L",
"name": "Avis Budget Group, Inc.",
"exchange": null,
"exchange_long": null,
"country": "gb",
"type": "equity",
"industry": "N/A",
"match_score": 125.64259,
"sentiment_score": 0.037414,
"highlights": [
{
"highlight": "NEW YORK, June 1, 2025 /PRNewswire/ -- R[+307 characters]",
"sentiment": 0.4588,
"highlighted_in": "main_text"
},
{
"highlight": "So What: If you purchased <em>Avis</em> [+293 characters]",
"sentiment": 0.6705,
"highlighted_in": "main_text"
},
{
"highlight": "Details of the case: According to the la[+330 characters]",
"sentiment": -0.6124,
"highlighted_in": "main_text"
},
{
"highlight": "of Avis Budget's vehicles in the America[+333 characters]",
"sentiment": -0.7579,
"highlighted_in": "main_text"
},
{
"highlight": "To join the <em>Avis</em> <em>Budget</em[+300 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "The Rosen Law Firm, P.A.\n\n275 Madison Av[+353 characters]",
"sentiment": 0.6808,
"highlighted_in": "main_text"
},
{
"highlight": "CAR Investors Have Opportunity to Lead <em>Avis</em> <em>Budget</em> <em>Group</em>, <em>Inc</em>. Securities Fraud Lawsuit",
"sentiment": -0.1779,
"highlighted_in": "title"
}
]
},
{
"symbol": "CAR.BA",
"name": "Avis Budget Group, Inc.",
"exchange": null,
"exchange_long": null,
"country": "ar",
"type": "equity",
"industry": "Industrials",
"match_score": 125.6474,
"sentiment_score": 0.037414,
"highlights": [
{
"highlight": "NEW YORK, June 1, 2025 /PRNewswire/ -- R[+307 characters]",
"sentiment": 0.4588,
"highlighted_in": "main_text"
},
{
"highlight": "So What: If you purchased <em>Avis</em> [+293 characters]",
"sentiment": 0.6705,
"highlighted_in": "main_text"
},
{
"highlight": "Details of the case: According to the la[+330 characters]",
"sentiment": -0.6124,
"highlighted_in": "main_text"
},
{
"highlight": "of Avis Budget's vehicles in the America[+333 characters]",
"sentiment": -0.7579,
"highlighted_in": "main_text"
},
{
"highlight": "To join the <em>Avis</em> <em>Budget</em[+300 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "The Rosen Law Firm, P.A.\n\n275 Madison Av[+353 characters]",
"sentiment": 0.6808,
"highlighted_in": "main_text"
},
{
"highlight": "CAR Investors Have Opportunity to Lead <em>Avis</em> <em>Budget</em> <em>Group</em>, <em>Inc</em>. Securities Fraud Lawsuit",
"sentiment": -0.1779,
"highlighted_in": "title"
}
]
}
]
},
{
"uuid": "47d296c4-f530-4db3-a381-683e2534d5a8",
"title": "ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Compass Diversified Holdings Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm- CODI",
"description": "NEW YORK, June 01, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Compass Diversified",
"keywords": "GuruFocus, Article, News, Marketwired, CODI",
"snippet": "NEW YORK, June 01, 2025 (GLOBE NEWSWIRE) --\n\nWHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Compass Diversified Hol...",
"url": "https://www.gurufocus.com/news/2900073/rosen-top-ranked-investor-counsel-encourages-compass-diversified-holdings-investors-to-secure-counsel-before-important-deadline-in-securities-class-action-first-filed-by-the-firm-codi",
"image_url": "https://static.gurufocus.com/images/global_logo_twitter_card.png",
"language": "en",
"published_at": "2025-06-01T12:00:02.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "CODI",
"name": "Compass Diversified",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Industrials",
"match_score": 81.25391,
"sentiment_score": 0.8413,
"highlights": [
{
"highlight": "NEW YORK, June 01, 2025 (GLOBE NEWSWIRE)[+334 characters]",
"sentiment": 0.8126,
"highlighted_in": "main_text"
},
{
"highlight": "ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages <em>Compass</em> <em>Diversified</em> Holdings Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm- CODI",
"sentiment": 0.87,
"highlighted_in": "title"
}
]
}
]
}
]
}
]
}
Sentiment
Live response for past 24 hours
{
"meta": {
"returned": 1,
"limit": 10
},
"data": [
{
"key": "us",
"total_documents": 513,
"sentiment_avg": 0.21930595411727902
}
]
}
Other details
Entity count
- 32,649